IR@PKUHSC  > 北京大学第一临床医学院
学科主题临床医学
Enhanced anti-tumor immunity generated by Rituximab-coated tumor cell vaccine
Wang, Huili1,2; Wang, Dongmei1,2; Li, Mengqiang3; Zhou, Chunxia1,2; Ma, Wenbo1,2; Su, Xiaosan1,2; Liu, Rongzhi4; Zhang, Shuren1,2
关键词Rituximab immunotherapy dendritic cells tumor cell vaccine
刊名CANCER LETTERS
2008-09-08
DOI10.1016/j.canlet.2008.03.042
268期:1页:129-136
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology
研究领域[WOS]Oncology
关键词[WOS]MONOCLONAL-ANTIBODY RITUXIMAB ; DENDRITIC CELLS ; BREAST-CANCER ; ANTIGENS ; LYMPHOMA ; RESPONSES ; EPITOPES ; CD20 ; SPECIFICITY ; MECHANISMS
英文摘要

Rituximab is a chimeric monoclonal antibody against CD20, and has been used to treat malignant tumors derived from B cell. We designed a tumor cell vaccine modified by Rituximab, and evaluated anti-tumor effect in human CD20 gene transfected mice tumor model in vivo, and in human CTLs induction by mixed lymphocyte tumor cell culture in vitro. The results demonstrated that the Rituximab-coated tumor cell vaccine had a significant therapeutic effect against tumor Pulmonary metastasis formation. Antibody depletion experiments showed CD8+ T Cells were essential for the anti-tumor effect but not NK cells. Capture rate Of tumor cells by DCs, which were detected by flow cytometry, was increased by adding Rituximab. The tumor specific cytolysis could be induced by Rituximab-coated tumor cell in human in vitro assay. This therapeutic strategy provides a simple way to potentialize CTLs function to combat cancer and may promote more clinical consideration in immunotherapy for tumors. Rituximab-coated tumor cell vaccine also expanded the clinical Rituximab applications. (C) 2008 Elsevier Ireland Ltd. All rights reserved.

语种英语
WOS记录号WOS:000260038900015
资助机构Shanxi Provincial cancer hospital and institute in China
引用统计
被引频次:2[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/63265
专题北京大学第一临床医学院
作者单位1.Peking Univ, Hosp 1, Beijing 100083, Peoples R China
2.Peking Union Med Coll, Inst Canc, Dept Immunol, Beijing 100021, Peoples R China
3.Chinese Acad Med Sci, Beijing 100021, Peoples R China
4.Chinese Acad Sci, Inst Microbiol, Beijing 100101, Peoples R China
推荐引用方式
GB/T 7714
Wang, Huili,Wang, Dongmei,Li, Mengqiang,et al. Enhanced anti-tumor immunity generated by Rituximab-coated tumor cell vaccine[J]. CANCER LETTERS,2008,268(1):129-136.
APA Wang, Huili.,Wang, Dongmei.,Li, Mengqiang.,Zhou, Chunxia.,Ma, Wenbo.,...&Zhang, Shuren.(2008).Enhanced anti-tumor immunity generated by Rituximab-coated tumor cell vaccine.CANCER LETTERS,268(1),129-136.
MLA Wang, Huili,et al."Enhanced anti-tumor immunity generated by Rituximab-coated tumor cell vaccine".CANCER LETTERS 268.1(2008):129-136.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Wang, Huili]的文章
[Wang, Dongmei]的文章
[Li, Mengqiang]的文章
百度学术
百度学术中相似的文章
[Wang, Huili]的文章
[Wang, Dongmei]的文章
[Li, Mengqiang]的文章
必应学术
必应学术中相似的文章
[Wang, Huili]的文章
[Wang, Dongmei]的文章
[Li, Mengqiang]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。